pharma · No medical condition. · Generalized Myasthenia Gravis
Anaxis Pharma
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2017
- Employees
- 7
- Programs
- 642
- Drugs
- 673
- Patents
- 0
KT-US-679-0788
Phase 3 · small molecule · Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody
KT-US-679-0788 for Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody is a Phase 3 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code KT-US-679-0788
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lacuna Pharma Pty Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody
- Status
- active
- Trials
- 1